Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Experts in Med Tech Regulation and Surgical Technologies join the Medical Sciences Division Industry Experts in Residence Scheme.

Dr Toni Day (left) and Professor Chris Cheng (right)

The Business Development Team for the Medical Sciences Division has announced the appointment of two new  experts to its Industry Experts in Residence Scheme. Dr Toni Day, Director of Quality and Regulatory Affairs at OrganOx, and Professor Chris Cheng, Consulting Professor in Vascular Surgery at Stanford and CEO of medical device company Koli Inc., became part of the scheme in December. 

The Industry Experts in Residence programme is managed by the MSD Business Development Team and Oxford University Innovation. It aims to give Oxford's research community access to world-leading expertise and advice across multiple sectors. Researchers can arrange meetings with industry experts to discuss their ideas and projects, and attend seminars give by these experts on a wide range of topics.

The scheme currently hosts experts in product design in biomedical engineering, drug discovery, and digital health, and the appointment of Dr Day and Professor Cheng has now made their expertise in Med Tech Regulation and Surgical Technologies available to researchers.

Dr Day holds a BSc Honours degree in Biochemistry and a DPhil in Neuropharmacology from the University of Oxford, and has worked for a number of start-up companies in the medical device, in vitro diagnostics and pharmaceutical arenas. She joined OrganOx Ltd in April 2011 to build the Quality Management System and the Regulatory Strategy. Toni commented: 'I am delighted to be part of the Industry Experts in Residence Scheme, and look forward to meeting researchers to discuss medical devices at all levels of the development lifecycle.' She is hosted in Oxford by the Oxford Medical CE Marking Forum (OxMCEF)

Professor Cheng is currently CEO of Koli, Inc., a medical device company developing a catheter-based solution for gallstone disease (spun out of Stanford Biodesign). He is also a Consulting Professor in Vascular Surgery at Stanford. He commented: 'I am thrilled to be at Oxford as part of the Expert in Residence program!  My colleagues in Surgery and Cardiovascular Medicine, as well as the Fellows at Exeter College, have made me feel at home since day one.  While I am here, I look forward to learning about the NHS, and am especially excited about engaging with students and faculty about academic collaborations with the medical device industry.' 

Maxine Allen, Head of Business Development and Partnering for the Medical Sciences Division, commented: 'The Industry Experts in Residence scheme is a fantastic opportunity for our researchers to develop translational strategies for their projects, and an innovative way to foster interaction between industry and academia.'

Find out more about the scheme and book an appointment with an expert 

______________________________________________________________________________________________

Upcoming workshops and talks

Professor Cheng will be running open, small group sessions about biomedical research, the medical device industry, entrepreneurship, choosing between academia and industry, and work-life balance over the coming term. These sessions will be from 2.30-4.30pm on Thurs 25 Jan, Thurs 8 Feb, Thurs 22 Feb, and Thurs 8 March in Exeter College Cohen Quad. Please send Prof. Cheng an email (christopher.cheng@exeter.ox.ac.uk) to confirm a place.  

Further workshops and events: 

Similar stories

Jenner Institute named Covid Innovation Heroes

The team at the University of Oxford’s Jenner Institute has been celebrated for their global pandemic work by The Oxford Trust’s Covid Innovation Heroes Award­ 2021.

Oxford joins consortium to advance quantum drug discovery with £6.8M grant from Innovate UK

Oxford University today joins a consortium led by the digital quantum computing company, SEEQC, to build and deliver a full-stack quantum computer for pharmaceutical drug development for Merck KGaA.

AIMday in Women's Health - registration for academics now open

Are you an academic interested in finding out how your knowledge can be used to solve industry challenges? Would you like to widen your network? Meet potential collaborators / future employees? Gain insights into relevant funding schemes? If you answer YES to any of the above, now is the time to register for the AIMday in Women's Health.

Six new Fellowships announced as part of Oxford-Bristol Myers Squibb Fellowships Programme

The Oxford - Bristol Myers Squibb (BMS) Fellowships Programme continued to demonstrate significant progress over the last year, despite the challenges associated with the global pandemic, including restricted lab access and work from home guidance. Today, we are pleased to announce six new Oxford-BMS Fellowships for 2021.

Anti-cancer drug derived from fungus shows promise in clinical trials

A new industry-academic partnership between the University of Oxford and biopharmaceutical company NuCana as found that chemotherapy drug NUC-7738, derived from a Himalayan fungus, has 40 times greater potency for killing cancer cells than its parent compound.

Oxford BioEscalator celebrates three years of innovation

The BioEscalator concept was born out of a shared need by academic researchers and their bioscience company collaborators for start-up incubator space close to academic labs. The vision was to develop a leading international centre for innovative bioscience with the potential to make a significant impact on healthcare. The incubator provides spin-outs and start-ups with laboratory and business support, enabling them to grow into leading bioscience ventures.